A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results